Lykos Therapeutics

05/09/2024

Today, we announce changes to the executive team. Amy Emerson will step down as CEO; Lykos COO, Michael Mullette, will serve as the interim CEO and Dr. David Hough will assume the role of CMO. We thank Amy for her leadership over the past decade and look forward to the future of working with the FDA to bring this potential new option to people living with PTSD.

https://news.lykospbc.com/2024-09-05-Lykos-Therapeutics-Announces-Appointments-of-Michael-Mullette-as-Interim-Chief-Executive-Officer-and-Dr-David-Hough-as-Chief-Medical-Officer

15/08/2024

Today, we announce our decision to reorganize Lykos Therapeutics in effort to focus on addressing FDA’s recent decision on our investigational treatment option for adults with PTSD. Learn more here: https://news.lykospbc.com/2024-08-15-Lykos-Therapeutics-Announces-Reorganization-to-Address-FDAs-Recent-Decision-on-Midomafetamine-Capsules-for-PTSD

11/08/2024

Thank youAmerican Psychological Association, for hosting another educational and collaborative event! We were thrilled to connect with everyone and share more about our mission to help adults living with .

09/08/2024

We remain steadfast in our commitment to working with the FDA to bring this potential new therapy to patients. Read our full announcement here: https://news.lykospbc.com/2024-08-09-Lykos-Therapeutics-Announces-Complete-Response-Letter-for-Midomafetamine-Capsules-for-PTSD

08/08/2024

In for this year’s ? We’re here too!

Visit our team at booth #315 to learn more about the neurobiology of .

01/08/2024

Today, we announce new initiatives and measures for additional oversight for midomafetamine capsules in combination with psychological intervention (“midomafetamine-assisted therapy”) for the treatment of in adults, if approved by the FDA:



- Establishing an independent advisory board

- Working with top behavioral health facilities

- Collaborating with others on training



Learn more about our dedication to patient safety here: https://news.lykospbc.com/2024-08-01-Lykos-Therapeutics-Announces-New-Initiatives-and-Measures-for-Additional-Oversight-for-Midomafetamine-Assisted-Therapy,-if-FDA-Approved

30/07/2024

Learn how PTSD is thought to influence the neurobiology of the brain: https://lykospbc.com/research-and-development/post-traumatic-stress-disorder/

26/07/2024

This National Minority Mental Health Awareness Month, learn more about , a serious mental health condition, here: https://bit.ly/4aAg7vA

22/07/2024

It’s time to address the unmet need for people living with post-traumatic stress disorder ( ); who may be impacted in all aspects of their lives, from strained personal relationships to impact on their ability to work.

Find more PTSD information and resources from NAMI here: https://bit.ly/4buZAtK

11/07/2024

Common post-traumatic stress disorder ( ) symptoms may include avoidance, reoccurring distressing memories, changes in activity level and mood.

Learn more about PTSD symptoms here: https://lykospbc.com/research-and-development/post-traumatic-stress-disorder/

04/07/2024

This we recognize those who serve and fight bravely to uphold our freedoms, especially the many who combat every day. Thank you for your service.

03/07/2024

It’s common for those living with to feel triggered during celebrations. Many may have strong reactions to fireworks due to the loud noises and flashing lights. Find more information and resources on how to cope here:

Apply for and manage the VA benefits and services you’ve earned as a Veteran, Servicemember, or family member—like health care, disability, education, and more.